Stable compositions of peptide epoxy ketones
The invention relates to pharmaceutical compositions that provide improved solubility and stability for peptide epoxy ketones. More specifically, the invention relates to pharmaceutical compositions comprising the peptide epoxy ketone proteasome inhibitor carfilzomib.
1. A ready to use, multi-dose liquid pharmaceutical composition suitable for injection, comprising:
(i) a liquid formulation comprising a non-volatile sugar acid, and carfilzomib or a pharmaceutically acceptable salt thereof;
(ii) wherein the liquid formulation comprises a solvent system suitable for injection and including at least one of ethanol, propylene glycol, polyethylene glycol, and water;
(iii) wherein the weight ratio of the non-volatile sugar acid to the carfilzomib or the pharmaceutically acceptable salt thereof ranges from 2:1 to 15:1; liquid formulation is present in a container in a quantity suitable for at least two independent and distinct administrations; and
(iv) wherein the liquid formulation is formulated to maintain degradation of the carfilzomib or the pharmaceutically acceptable salt thereof at a level of less than 10% when the liquid formulation is stored over at least one month at 25 degrees Celsius and 60% relative humidity.
2. The pharmaceutical composition of claim 1 , wherein the non-volatile sugar acid is selected from the group consisting of lactobionic acid, glycolic acid, malic acid, citric acid, lactic acid, mandelic acid, and tartaric acid.
3. The pharmaceutical composition of claim 1 , wherein the solvent system comprises ethanol and propylene glycol.
4. The pharmaceutical composition of claim 1 , wherein the solvent system comprises ethanol and polyethylene glycol.
5. The pharmaceutical composition of claim 1 , wherein the non-volatile sugar acid is lactobionic acid.
6. The pharmaceutical composition of claim 5 , wherein the concentration of the carfilzomib or the pharmaceutically acceptable salt thereof in the solvent system ranges from about 0.1 to about 10.0 mg/mL and the weight ratio of the carfilzomib or the pharmaceutically acceptable salt thereof to lactobionic acid ranges from about 2:1 to 15:1.
7. The pharmaceutical composition of claim 6 , wherein the solvent system comprises ethanol, propylene glycol, and water.
8. The pharmaceutical composition of claim 6 , wherein the solvent system comprises ethanol, polyethylene glycol, and water.
9. The pharmaceutical composition of claim 1 , wherein:
(i) the non-volatile sugar acid is lactobionic acid, and wherein the weight ratio of the lactobionic acid to carfilzomib or the pharmaceutically acceptable salt thereof ranges from about 2:1 to 15:1; and
(ii) the solvent system includes ethanol, propylene glycol, and water, and wherein the ethanol and propylene glycol comprise more than about 50% (v/v) of the solvent system, wherein the concentration of the carfilzomib or the pharmaceutically acceptable salt thereof ranges from about 1 mg/mL to about 6 mg/mL.
10. The pharmaceutical composition of claim 1 wherein:
(i) the non-volatile sugar acid is lactobionic acid, and wherein the weight ratio of the lactobionic acid to carfilzomib or the pharmaceutically acceptable salt thereof ranges from about 4:1 to 7:1; and
(ii) the solvent system includes ethanol, polyethylene glycol, and water, and wherein the ethanol and polyethylene glycol comprise more than about 50% (v/v) of the solvent system, wherein the concentration of the carfilzomib or the pharmaceutically acceptable salt thereof ranges from about 1 mg/mL to about 6 mg/mL.
11. The pharmaceutical composition of claim 1 , wherein the liquid formulation is formulated to be stable at room temperature for at least 3 months.
12. A ready to dilute, multi-dose liquid pharmaceutical composition, comprising:
(i) a liquid formulation comprising a non-volatile sugar acid and carfilzomib or a pharmaceutically acceptable salt thereof, wherein the weight ratio of the non-volatile sugar acid to the carfilzomib or the pharmaceutically acceptable salt thereof ranges from 2:1 to 15:1;
(ii) wherein the liquid formulation comprises a solvent system suitable for injection upon dilution with a suitable diluent, the solvent system including at least one of ethanol, propylene glycol, polyethylene glycol, and water;
(iii) wherein the liquid formulation is present in a container in a quantity suitable for at least two independent and distinct administrations; and
(iv) wherein the liquid formulation is formulated to maintain degradation of the carfilzomib or the pharmaceutically acceptable salt thereof at a level of less than 10% when the liquid formulation is stored over at least one month at 25 degrees Celsius and 60% relative humidity.